Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4581 - Timing to achieve complete response (CR) after definitive chemoradiotherapy (ChRT) in patients with squamous cell carcinoma of the anal (SCCAC) with and without HIV infection: a multicenter retrospective study


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Marcos Camandaroba


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


M.P.G. Camandaroba1, S. Iseas2, R.G. Taboada1, C.P. Oliveira1, C.D.C. Mauro1, M.P. Xerfan1, M. Barros1, V.H.F. de Jesus1, T.C. Felismino1, C.A. Mello1, R.P. Riechelmann1

Author affiliations

  • 1 Clinical Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 2 Oncology, Bonorino Udaondo Hospital, C1264AAA - Buenos Aires/AR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4581


The definitive treatment for localized SCCA is ChRT in combination with infusional 5-FU. A meta-analysis of published studies conducted by our group showed that HIV-positive patients (pts) are less cured by ChRT. However, short follow up times may have underestimated the true response rate of HIV-positive pts. We aimed to compare the timing to achieve CR between HIV-negative and positive pts and outcomes according to chemotherapy regimen (Nigro vs ACT2).


Retrospective multicenter comparative cohort of consecutive pts with histological diagnosis of SCCA and localized disease who received definitive ChRT. Pts’ characteristics and outcomes were compared according to HIV status. The primary endpoint was CR rate defined by absence of clinical and radiological evidence of disease.


A total of 179 patients with SCCA were included: 43 (24%) were HIV-positive and 136 (76%) were HIV-negative. HIV-positive pts were more commonly men: 28 (65%) vs 24 (17.6%) (p < 0.001) and had clinical stage III: 22 (51%) vs 60 (44%). The overall CR rate was 74.4% vs 83.1% for HIV-positive and negative pts, respectively (P = 0.206). Among pts who achieved a CR (N = 145), the rates of CR for HIV-positive vs negative pts were, respectively: 32.5% vs 67% at 6 months evaluation and 41.8% vs 16.1% after 6 months (6 to 18 months) post ChRT (p < 0.001). More HIV-positive pts underwent salvage surgery: 14 (35.2%) vs 21 (15.4%) (p < 0.01). The overall CR rates of HIV-positive pts were 71.4% (10 out of 14) with ACT2 and 63% (14 out of 22) with Nigro. For HIV-negative, the CR rates were: 90.3% (28 out of 31) for ACT2 and 80.2 % (73 out of 91) for Nigro.


Delayed CR was more frequently observed among HIV-positive pts. This finding has clinical implications because waiting longer to define CR among these pts may prevent unnecessary anorectal amputations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.